A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Trial details
- Registry ID
- NCT07271667
- Phase
- Phase 2
The FDA approved Zanubrutinib (BRUKINSA®) on 14 Nov 2019.
Drug identity checked against registry records
Also recorded as BRUKINSA®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesNCT07271667 | CRIS | Phase 2 | Recruiting | 2027-11Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2019-11-14Day | Zanubrutinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213217", "applicant_as_listed_by_fda": "BEONE MEDICINES USA", "brand_names": ["BRUKINSA"], "active_ingredients": ["ZANUBRUTINIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20191114", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |